Product Name: EphA1 (778-784) pY781
Product Number: PE-04ALV80
Size: 200 µg      Price:35.00
1 mg      $US71.00
5 mg      153.00
Peptide Name: EphA1 (778-784) pY781

Product Use: Services as a blocking peptide for use with the EphA1-pY781 rabbit polyclonal antibody (Cat. No.: AB-PK605) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T-loop between subdomains VII and VIII. Y781 phosphorylation stimulates phosphotransferase activity.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: DGT-pY-ETQ

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: βAla-Cys
Peptide Modifications Other: Phosphorylated

Peptide Molecular Mass Calculated: 1066.94 Da

Peptide Purity Percent after Synthesis and Purification: >80

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Related Product 1: EphA1 - pY781 phosphosite-specific antibody (Cat. No.: AB-PK605)

Scientific Background: EphA1 is a protein-tyrosine kinase of the TK group and Eph family. It is activated by binding of ephrin-A1 on a presenting cell, which is likely to induce dimerization and autophosphorylation. This kinase is moderate to highly expressed in most tested human tissues. Orthologues of EphA1 are highly conserved in mammals and birds. EphA1 has been implicated in mediating developmental events, particularly in the nervous system. EphA1 seems to be a marker of the differentiated normal epidermis, and its downregulation in nonmelanoma skin cancer may contribute to carcinogenesis of these very frequent human tumors. EphA1 represents a new potential prognostic marker and therapeutic target in nonmelanoma skin cancer. EphA1 has also been linked with the development of glioblastomas, head and neck cancer and breast carcinomas (pleomorphic lobular).